Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.01, $0.14 better than the analyst estimate of $0.87. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.48 billion.

“We had a very good second quarter where we delivered strong performance for Eliquis and Opdivo,and achieved important regulatory and data milestones supporting our Immuno-Oncology portfolio,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we are focused on robust commercial execution and the evolution of our diversified pipeline to deliver transformational medicines to the patients we serve.”

GUIDANCE:

Bristol-Myers Squibb sees FY2018 EPS of $3.55-$3.65, versus prior of $3.35-$3.45 and the consensus of $3.42.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.